Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06129500
Other study ID # 2022-23-07
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 17, 2023
Est. completion date June 24, 2024

Study information

Verified date November 2023
Source University of Exeter
Contact Jan Freeman, MSc
Phone 01392 726449
Email jf693@exeter.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this case series is to explore whether a talking therapy, specifically Cognitive Behavioural Therapy (CBT) is acceptable and feasible in the management of mood-driven impulsive behaviours in people with bipolar disorder (BD). The main questions it aims to answer are: - Whether CBT Is a feasible intervention for participants with BD who report mood-driven, problematic impulsive behaviours. - Whether CBT for mood-driven, problematic impulsive behaviours (CBT-PIB) is acceptable to service users with BD and therapists. - Whether clinical outcomes are consistent with the potential for this novel intervention to offer clinical benefit to participants with BD. The study also hopes to: - conduct a preliminary examination of the safety of CBT-PIB and the research procedures. - gather information on the potential mechanisms of action of CBT-PIB and, - gather information on the types of mood-driven impulsive behaviours individuals with BD may seek support for. Participants will: - be offered up to 12 individual sessions of CBT focusing on mood-driven impulsive behaviours. - be asked to complete a battery of self-report measures (5) when they enter the study and at the start and end of treatment. - be asked to track mood and impulsive behaviours by completing a brief set of measures (3) weekly during the two-week baseline phase, the intervention phase and the 2-week post-intervention phase. - be asked to complete a survey on the acceptability of the intervention and - be invited to an optional semi-structured interview on their research experience.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date June 24, 2024
Est. primary completion date June 10, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - meeting diagnostic criteria for Bipolar I or II Disorder (SCID-5- Structured clinical interview for depression ) - able to identify at least one impulsive, problematic behaviour to target during the intervention; - participants will require working knowledge of written and spoken English, sufficient to be able to make use of therapy and to be able complete research assessments without the need of a translator. Exclusion Criteria: - major depressive episode (identified through SCID-DSM-5); - current experience of mania; - current/past learning disability (IQ of less than 70 with impairment of social and adaptive functioning) - organic brain change or substance dependence (drugs and alcohol) that would compromise ability to use therapy; - current marked risk to self (i.e. self-harm or suicide) that we deem could not be appropriately managed in by the therapy site; - currently lacking capacity to give informed consent; - currently receiving other psychosocial therapy for impulsivity or bipolar disorder; - current engagement in another psychological intervention addressing bipolar disorder or impulsivity; - presence of another area of difficulty that the therapist and client believe should be the primary focus of intervention (for example, Post-Traumatic Stress Disorder, psychosis).

Study Design


Intervention

Behavioral:
Cognitive Behavioural Therapy for Problematic Impulsive Behaviours
Up to 12 sessions of Cognitive Behavioural Therapy adapted to focus on mood-driven impulsivity in adults with bipolar disorder.

Locations

Country Name City State
United Kingdom AccEPT Clinic Exeter Devon

Sponsors (4)

Lead Sponsor Collaborator
University of Exeter Devon Partnership NHS Trust, Somerset NHS Foundation Trust, Southern Health NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall acceptability and feasibility of the CBT protocol measured by the Client Satisfaction Questionnaire CBT-PIB qualitative and quantitative feedback from participants Post-intervention at week 16
Primary rates of clinically significant and reliable change in mood measured by the Patient health questionnaire (PHQ-9) used to monitor the severity of depression and response to treatment Through study completion, an average of 18 weeks
Primary rates of clinically significant and reliable change in symptoms of mania measured by the Altman Self-Rating Mania Scale scale that assesses the presence and severity of manic or hypomanic symptoms Through study completion, an average of 18 weeks
Primary Changes in management of impulsivity measured by the Visual Analogue Scale Visual scale measuring the severity and impact of general and behavioural impulsivity Through study completion, an average of 18 weeks
Primary Number of participants with intervention-related adverse events assessed by the adverse events form qualitative form eliciting adverse events Through study completion, an average of 18 weeks
Secondary rates of clinically significant and reliable change in general daily functioning as measured by the Work and Social Adjustment Scale scale assesses changes in the impact of a person's mental health difficulties on their ability to function in terms of work, home management, social leisure, private leisure and personal or family relationships. At baseline, 2 weeks and 14 weeks
Secondary rates of clinically significant and reliable change in quality of life as measured by the Brief Quality of Life in Bipolar Disorder self-report measure of changes in disorder-specific quality of life At baseline, 2 weeks and 14 weeks
Secondary rates of clinically significant and reliable change in symptoms of anxiety as measured by the General Anxiety Disorder Assessment (GAD7) scale measuring changes in symptoms of anxiety At baseline, in 2 weeks and in 14 weeks
Secondary rates of clinically significant and reliable change in overall wellbeing as measured by the Warwick-Edinburgh Mental Well-being Scale scale measuring changes in positive features of mental health At baseline, in 2 weeks and in 14 weeks
Secondary rates of clinically significant and reliable change in impulsivity measured by the Short Urgency, Premeditation (lack of), Perseverance (lack of), Sensation Seeking, Positive Urgency, Impulsive Behavior Scale Scale measuring changes in 5 domains of impulsive behaviour At baseline, in 2 weeks and in 14 weeks
See also
  Status Clinical Trial Phase
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT02855762 - Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder N/A
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Completed NCT02513654 - Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects Phase 1
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Recruiting NCT06197048 - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder N/A
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Not yet recruiting NCT04432116 - Time and Virtual Reality in Schizophrenia and Bipolar Disorder N/A
Terminated NCT02909504 - Gao NARASD Lithium Study Phase 4
Completed NCT02970721 - Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
Terminated NCT02893371 - Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study